# Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-versus-placebo-as-second-line-therapy-in-patients-from-asia-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shukui Qin,Zhendong Chen,Weijia Fang,Zhenggang Ren,Ruocai Xu,Baek‐Yeol Ryoo,Zhiqiang Meng,Yuxian Bai,Xiaoming Chen,Xiufeng Liu,Juxiang Xiao,Gwo Fuang Ho,Yimin Mao,Xin Wang,Jieer Ying,Jianfeng Li,Wenyan Zhong,Yu Zhou,Abby B. Siegel,Chunyi Hao |
| Citations | 191 |
| DOI | 10.1200/jco.22.00620 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00620?role=tab |
| OpenAlex ID | https://openalex.org/W4310595719 |
| PMID | 36455168 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Gwo Fuang Ho](https://scholariq.org/researchers/gwo-fuang-ho/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.